Jasper Initiates SPOTLIGHT Trial with First Patient Dosed for CIndU Treatment with Briquilimab

Biotechnology firm Jasper Therapeutics has initiated its Phase 1b/2a clinical trial, known as SPOTLIGHT, for the treatment of chronic inducible urticaria (CIndU) using a novel antibody, briquilimab. The study involves administering a single dose of the drug subcutaneously at two varying levels to adult patients with cold urticaria or symptomatic dermographism. The company, which is also conducting the BEACON study for chronic spontaneous urticaria (CSU), anticipates preliminary results in the latter half of 2024. The SPOTLIGHT trial aims to enroll around 15 patients and is taking place at four European Union sites. The study's primary focus is on the safety and tolerability of briquilimab, with secondary goals to assess its efficacy and pharmacokinetics.

Briquilimab is an aglycosylated monoclonal antibody that targets the c-Kit receptor, which is involved in mast cell-driven diseases such as chronic urticaria. The drug has shown efficacy and safety in over 145 participants and is also being studied for lower to intermediate risk myelodysplastic syndromes (MDS) and as a conditioning agent for cell therapies for rare diseases.

Jasper Therapeutics is a clinical-stage company developing briquilimab for the treatment of chronic mast and stem cell diseases and as a conditioning agent for stem cell transplants. 

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!